Home › NCT05389904

Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile

A Pre-emptive Prevention Bundle for Patients at High Risk for Hospital-onset Clostridioides Difficile

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients admitted to ICU or Oncology units and identified to carry C. Difficile via VRE swab

Exclusion Criteria:

* Patients not identified as carriers of C. difficile and patients not admitted to ICU or oncology units

About the study

Clostridioides difficile (C. difficile) is the most common healthcare-associated pathogen, causing \>500,000 infections and \>29,000 deaths per year in the US. Traditional approaches to reduce hospital-onset CDI focus on identifying, isolating, and treating symptomatic patients to prevent transmission to other patients. Recent genomic epidemiology studies, however, suggest that most hospital-onset CDI cases are attributable to asymptomatic carriers who either progress from colonization to active infection themselves or transmit C. difficile to other patients while asymptomatic. This trial will evaluate an intervention to pre-emptively identify asymptomatic C. difficile carriers and then implement a patient-tailored prevention package to protect the carrier from progression to active infection and to prevent transmission from the carrier to other patients.

What is being tested

• Arm 1: Routine care (other)
• Arm 2: Preemptive C. difficile infection prevention bundle (other)

Sponsor: Brigham and Women's Hospital · Participants: 300 · Started: Jul 25, 2022

Contact the study team

• Meghan A Baker, MD, SCD · Phone: 617-732-8881

Official record on ClinicalTrials.gov — NCT05389904

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.